Samsung Biologics announced on Jan. 12, 2022 that it plans to start building a new facility (designated Plant 5) at Songdo in Incheon, South Korea, this year. The facility will offer manufacturing for multi-modal products, including cell and gene therapies and next-generation vaccines that utilize messenger RNA (mRNA), plasmid DNA, and viral vectors. The expansion is part of the company’s 2022 growth plan.
The new facility will be an addition to the mRNA vaccine drug substance (DS) manufacturing suite that the company is currently adding to its existing facility in Songdo. The mRNA vaccine DS facility is expected to be ready for current good manufacturing practice operations within the earlier part of this year, according to a company press release.